Abstract:Abstract Topical tacrolimus 0.1% is a widely accepted treatment for localized vitiligo. However, emerging Janus kinase inhibitors like tofacitinib show promise. Existing evidence for topical tofacitinib largely comes from open-label, uncontrolled studies and case reports, often in combination with other therapies. This prospective, 16-week, single-blinded, split-body study evaluated the efficacy and tolerability of topical tofacitinib 2% ointment vs. topical tacrolimus 0.1% ointment applied twice daily in a cohort of 25 patients with limited vitiligo. Participants aged ≥ 5 years with a diagnosis of nonsegmental vitiligo, limited to ≤ 10% body surface area, and at least two symmetrical vitiligo patches that had been active in last 12 months were included. After informed consent was obtained, vitiliginous patches on either side of the body were randomized to receive either topical tofacitinib or topical tacrolimus. The total duration of therapy was 16 weeks, and patients were followed up every 4 weeks. The primary outcome was Vitiligo Noticeability Scale (VNS) of two symmetrical target patches at week 16 as reported by patients, with a VNS of 4 (‘a lot less noticeable’) or 5 (‘no longer noticeable’) considered as treatment success. Secondary outcomes included clinician-reported percentage repigmentation, time to attainment of treatment success and incidence of adverse effects. The study cohort, comprising 25 patients analysed for 50 vitiligo patches, had a mean age of 22.4 years (range 5–59). The topical tofacitinib group achieved a VNS of 4 or 5 (considered treatment success) in 14 patients (56%), compared with 11 (44%) in the tacrolimus group (P = 0.40). Clinicians observed significant repigmentation exceeding 75% in 15 patients within the tofacitinib group and 13 patients within the tacrolimus group (P = 0.57). The mean (SD) time to attain treatment success was 12.4 (3.8) weeks for tacrolimus and 10.0 (4.4) weeks for tofacitinib. Strikingly, tofacitinib demonstrated treatment success as early as 4 weeks in three patients, whereas no such rapid success was observed in the tacrolimus group. Adverse effects, predominantly mild, included transient erythema (n = 1) and burning sensations (n = 5) with tacrolimus, while tofacitinib led to application-site pain and pruritus in one patient each (P = 0.12). Limitations of our study include the small sample size, short treatment duration and single-blinded study design. In summation, this study unveils the efficacy of both topical tofacitinib and tacrolimus in repigmenting vitiligo lesions. Tofacitinib exhibits a higher, though statistically nonsignificant, treatment success rate and a swifter onset of repigmentation, indicating its potential as a robust therapeutic option for limited vitiligo.

Topical tacrolimus therapy for vitiligo

A clinical evaluation of topical tacrolimus treatment for patients with vitiligo

Therapeutic Effect of Topical Tacrolimus in Vitiligo Treatment

Efficacy and Safety of Tacrolimus and Pimecrolimus Ointment on Vitiligo:A Systematic Review

Combination of topical tacrolimus ointment and NB-UVB for vitiligo on the face and neck

P090 A randomized study to compare the efficacy of topical tofacitinib vs. topical tacrolimus in treatment of patients with unstable vitiligo

A placebo-controlled clinical trial of tacalcitol for the treatment of vitiligo

Clinical Study of Combination Therapy of 308nm Excimer Laser and Topical Tacrolimus for Treatment of Vitiligo

Effcacy and Safety of Tacalcitol and Calcitriol on Vitiligo:A Systematic Review

Randomized controlled trial of 308nm excimer laser combined with topical tacrolimus ointment in the treatment of vitiligo

Clinical Efficacy and Safety of Tacrolimus Ointment in Patients with Vitiligo

Effect of calcipotriol betamethasone ointment on treatment of non-generalized vitiligo

Efficacy and Tolerability of Topical Tacrolimus in the Treatment of Atopic Dermatitis: a Systematic Review of Randomized Controlled Trials

Topical tacalcitol and MEL308 nm:a synergistic combination for the treatment of vitiligo

Efficacy and Safety of Topical Tacrolimus Microemulsion Applied Twice Daily in Patients with Mild to Moderate Scalp Psoriasis

Topical Tacalcitol and 308-Nm Monochromatic Excimer Light: A Synergistic Combination for the Treatment of Vitiligo

Topical tacrolimus suppresses the expression of vascular endothelial growth factor and insulin-like growth factor-1 in late anagen.

Efficacy and Safety of Tacrolimus Ointment in Treatment of Atopic Dermatitis of Child and Adult in 51 Patients

Efficacy and safety of tacrolimus ointment for facial sensitive skin in adults

Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases

The Therapeutic Effect of Tacrolimus Ointment and Intensive Moisturizing Cream Containing Prinsepia Utilis Royle oil Extract in Treating 64 Cases of Corticosteroid-dependent Dermatitis